Injection day strategies Most users on the pyridoxine compound report that injection day nausea, while reduced compared to standard semaglutide, can still be noticeable at higher doses
10.1172/JCI105126 J
Cristina Mathewman, PhD
however, effective strategies to selectively eliminate senescent endothelial cells and restore vascular function remain lacking
The Regulatory Reality of 2026: What Actually Changed In late 2023, the FDA moved 19 peptides, including BPC-157, to what's known as "Category 2" status under its framework for bulk drug substances used in compounding, identifying them as substances that "may present significant safety risks." The concern, as stated in FDA guidance, centered on the limited large-scale human data and questions about immunogenicity
For physically active users, they may subtly affect recovery, endurance, and performance over time